Molecular therapy for Visceral pain: Menin (MEN1) decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 16/February/2015, 23.07

Molecular therapy for Visceral pain: Menin (MEN1) decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 16/February/2015, 23.07

Molecular therapy for Visceral pain: Menin (MEN1) decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 16/February/2015, 23.07 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Molecular therapy for Visceral pain: Menin (MEN1) decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 16/February/2015, 23.07, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that Menin, by increasing the expression of its target gene, it may decrease visceral pain in patients with Irritable Bowel Syndrome.  Thus, pharmacological formulations encompassing “Menin activators  may be used to treat visceral pain.

Amount: $ 500*

Undisclosed information: How Menin decreases visceral pain

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org